Category Archives: Cancer and neoplasms
Cancer and neoplasms
Randall Spotlights Surgical and Non-Surgical Advances in Musculoskeletal Oncology
Sep
R. Lor Randall, MD, FACS Researchers in orthopedic oncology continue to develop innovative techniques for both the surgical and non-surgical management of benign and malignant tumors of bone and connective soft tissues. These solutions require a multidisciplinary approach, further emphasizing the importance of educating oncologists across all specialties on the current landscape of medical and […]
Cancer and neoplasms
Extended Prognosis in Patients with Carotid & Aortic Body Tumors: Long-Term Outcomes Study
Sep
The following is a summary of “Long-Term Outcomes of Patients With Carotid and Aortic Body Tumors,” published in the July 2023 issue of the Cardiovascular Disease by Verghis et al. Chemodectomas are neoplasms originating from parasympathetic nonchromaffin cells and are frequently detected in the aortic and carotid bodies. They are typically non-malignant but can induce […]
Cancer and neoplasms
Peanut Allergy Market to Accelerate Substantially by 2032, Examines DelveInsight | Leading Companies – Vedanta, Allergy, COUR Pharmaceutical, DBV, Aimmune, Novartis, NIAID, Alladapt Immunotherapeutics
Sep
New York, USA, Sept. 12, 2023 (GLOBE NEWSWIRE) — Peanut Allergy Market to Accelerate Substantially by 2032, Examines DelveInsight | Leading Companies – Vedanta, Allergy, COUR Pharmaceutical, DBV, Aimmune, Novartis, NIAID, Alladapt Immunotherapeutics The dynamics of the peanut allergy market are anticipated to change in the coming years owing to the improvement in the diagnosis […]
Cancer and neoplasms
Exercise interventions on body composition and quality of life of overweight/obese breast cancer survivors: a meta-analysis
Sep
Trayes KP, Cokenakes SEH. Breast Cancer Treatment. Am Fam Physician. 2021;104(2):171–8. PubMed Google Scholar Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA-Cancer J Clin. 2021;71(3):209–49. PubMed Google Scholar Ganz PA, Goodwin […]
Sep
“According to our findings, specific [flow cytometry] characteristics such as Ogata score and specific PAs correlate with mutational patterns, which can predict outcome and treatment response in the majority of patients,” according to the study authors. The presence of cytomorphological and flow cytometry features correlated with both prognosis and mutational patterns that may be predictive […]
Cancer and neoplasms
Hoth Therapeutics Advances Cancer Treatment with HTKIT A Breakthrough in Mast Cell Neoplasms
Sep
On September 11, 2023, Hoth Therapeutics made an exciting announcement regarding their latest breakthrough in cancer treatment. The FDA has officially accepted the pre-investigational new drug (pre-IND) submission for their groundbreaking molecular entity called HT-KIT. This new development shows immense promise in combating mast cell derived cancers and anaphylaxis. What makes HT-KIT even more remarkable […]
HT-KIT received Orphan Drug Designation from FDA for its mRNA Frame Shifting Cancer Therapeutic Hoth intends to initially target mast cell neoplasms for development of HT-KIT, which is a rare, aggressive cancer with poor prognosis NEW YORK, Sept. 11, 2023 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has submitted a request […]
